# Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/QNTM
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 8, 2026

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) last closed at $3.45, near the bottom of its 52-week range of $2.07–$31.91. Composite market sentiment across 1 analysis is neutral (-3 on a −100 to +100 scale), as of Aug 8, 2026.

## What the data says

At $3.45, the stock trades near the low end of a 52-week range that runs from $2.07 to $31.914. That range is unusually wide — the high is roughly nine times the low — and the current price sits closer to the floor than the ceiling, so the past year has covered a very large span rather than a narrow band. With a market capitalization of about $22 million, this is a micro-cap name, and price moves of that magnitude are typical of companies at that size.

The profitability figures show a business that is not currently earning. Reported profit margin is zero, and the forward price-to-earnings ratio of -0.44 is negative, which is what happens when expected earnings are below zero rather than a conventional earnings multiple. Price-to-book stands at roughly 33.8, meaning the market values the shares well above the accounting value of the company's net assets — a pattern common where value rests on development-stage assets rather than current results. Beta of 0.43 places historical movement at well under the market's, so day-to-day direction has been driven more by company-specific developments than by broad index moves.

Recent news flow is entirely company-specific rather than sector-wide. The most recent items, from late July 2026, cover the announced intention to settle debt and the subsequent closing of that debt settlement, following a private placement whose initial tranche closed in March 2026. The remainder of the flow consists of a series of corporate updates issued in March, April, and June 2026. Taken together, the headlines center on financing and balance-sheet housekeeping alongside routine company communications, with no items in this set tied to wider healthcare or biotechnology industry events.

## About Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company that develops treatments for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. It operates through two segments: Biopharmaceutical Innovation, which covers its drug development portfolio, and Strategic Investments, which holds a portfolio of loans secured by residential property. The company was founded in 1998 and operated as FSD Pharma before adopting its current name in August 2024.

Its lead candidate, Lucid-MS, is a patented new chemical entity aimed at preventing and reversing myelin degradation, the process underlying multiple sclerosis, and has entered Phase 2 clinical testing. Other programs include FSD-PEA, being prepared for a Phase 2 trial in inflammatory conditions such as mast cell activation syndrome; Lucid-PSYCH, directed at major depressive disorder; and unbuzzd, a dietary supplement related to alcohol misuse.

## Company profile

- Symbol: QNTM
- Exchange: NASDAQ
- Security type: Stock
- Sector: Healthcare
- Industry: Biotechnology
- Composite sentiment: neutral (-3 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $22.08M |
| Enterprise value | $16.37M |
| Forward P/E | -0.44 |
| Price to book | 33.82 |
| Beta | 0.43 |
| Net margin | 0.00% |
| 52-week high | $31.91 |
| 52-week low | $2.07 |
| Average volume | 249.77K |

## Related stocks

- ZYUS.V
- LABS.TO
- ROMJ.V
- QNTM.CN
- GSD.V
- ALGO.NE
- IAN.CN
- MRV.TO

## Recent news

- [Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-advances-ms-191500472.html) — Aug 3, 2026
- [Quantum BioPharma Announces Closing of Debt Settlement](https://www.globenewswire.com/news-release/2026/07/30/3335726/0/en/Quantum-BioPharma-Announces-Closing-of-Debt-Settlement.html) — Jul 30, 2026
- [Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-executive-outlines-183500295.html) — Jul 28, 2026
- [Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-developing-two-183000333.html) — Jul 22, 2026
- [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.benzinga.com/trading-ideas/movers/26/07/60573672/12-health-care-stocks-moving-tuesday-s-pre-market-session) — Jul 21, 2026
- [Quantum BioPharma Announces Intention to Settle Debt](https://www.globenewswire.com/news-release/2026/07/20/3330162/0/en/Quantum-BioPharma-Announces-Intention-to-Settle-Debt.html) — Jul 20, 2026
- [Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-expands-clinical-184530119.html) — Jul 15, 2026
- [Why Quantum BioPharma (QNTM) Is 'One to Watch'](https://finance.yahoo.com/healthcare/articles/why-quantum-biopharma-qntm-one-183000482.html) — Jul 10, 2026
- [Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-showcases-unique-190000006.html) — Jul 1, 2026
- [Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study](https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-reaches-key-193000702.html) — Jun 29, 2026

## Frequently asked questions

### What is the current market sentiment for QNTM?

As of Aug 8, 2026, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries neutral (-3 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has QNTM stock been performing?

Quantum Biopharma Ltd. Class B Subordinate Voting Shares last closed at $3.45, near the bottom of its 52-week range of $2.07–$31.91.

### What is QNTM's market cap and valuation?

Quantum Biopharma Ltd. Class B Subordinate Voting Shares has a market capitalization of about $22.08M.

### What sector is QNTM in, and who are its competitors?

Quantum Biopharma Ltd. Class B Subordinate Voting Shares operates in the Healthcare sector, specifically Biotechnology. Comparable companies include ZYUS.V, LABS.TO, ROMJ.V, QNTM.CN, GSD.V.

### Where can I find a full analysis of QNTM?

The full QNTM report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/QNTM/v/1) (account and access required)